Literature DB >> 12963206

Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion.

Jerome M McDonald1, Bryan F Meyers, Tracey J Guthrie, Richard J Battafarano, Joel D Cooper, G Alexander Patterson.   

Abstract

BACKGROUND: The optimal therapy for symptomatic pericardial effusions remains controversial. This paper compares outcomes after the two most commonly used techniques, percutaneous catheter drainage and operative subxiphoid pericardial drainage.
METHODS: We performed a 5-year retrospective, single-institution study to analyze outcomes after either percutaneous catheter drainage or subxiphoid open pericardial drainage for symptomatic pericardial effusions.
RESULTS: Symptomatic pericardial effusions in 246 patients were treated by open pericardiotomy and tube drainage (n = 150) or percutaneous catheter drainage (n = 96). Drainage duration, total drainage volume, and duration of follow-up (2.6 years) were similar in both groups. Effusions were classified malignant in 79 (32%) patients and benign in 167 (68%) patients. No direct procedural mortality occurred, but the hospital mortality was 16 patients (10.7%) in the open group and 22 (22.9%) in the percutaneous group (p = 0.01) The 5-year survival rate was 51% in the open group versus 45% in the percutaneous group, despite a greater percentage of the open group having a preoperative malignant diagnosis (35% versus 28%). Symptomatic effusions recurred in 16.5% of the percutaneous group compared with 4.6% in the open group (p = 0.002), and sclerosis did not appear to reduce recurrence rates (10.7% with sclerosis versus 15.6% without; p > 0.05). The diagnosis of malignancy was confirmed in 16 of 27 (59%) percutaneous procedures performed on patients with known malignancy. In the open group, cytologic and pathologic evaluation of the pericardial specimen revealed malignancy in 32 of 52 (62%) patients with known malignancy.
CONCLUSIONS: Subxiphoid and percutaneous pericardial drainage of symptomatic pericardial effusions can be performed safely; however, death occurs from underlying disease. Open subxiphoid pericardial drainage with pericardial biopsy appears to decrease recurrence but does not improve diagnostic accuracy of malignancy over cytology alone.

Entities:  

Mesh:

Year:  2003        PMID: 12963206     DOI: 10.1016/s0003-4975(03)00665-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  18 in total

1.  Blind subxiphoid pericardiotomy to relieve critical acute hemopericardium: a final report.

Authors:  Y Kurimoto; K Maekawa; K Tanno; K Mori; T Koyanagi; T Ito; N Kawaharada; A Watanabe; T Higami; Y Asai
Journal:  Eur J Trauma Emerg Surg       Date:  2012-06-21       Impact factor: 3.693

Review 2.  Landmark Trials in the Surgical Management of Mesothelioma.

Authors:  Taylor Kantor; Elliot Wakeam
Journal:  Ann Surg Oncol       Date:  2021-01-31       Impact factor: 5.344

Review 3.  [Pericardial effusion. Differential diagnostics, surveillance and treatment].

Authors:  S Lehmann; T Schröter; S Thomas; A Lehmann; I Altmann; S Leontyev; S Leotyev; F Bakhtiary; J Seeburger; J Garbade; A Rastan; F W Mohr
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

4.  Subxiphoid pericardiostomy in the management of pericardial effusions: case series analysis of 368 patients.

Authors:  N Becit; Y Unlü; M Ceviz; C U Koçogullari; H Koçak; Y Gürlertop
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

5.  Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.

Authors:  Danielle El Haddad; Cezar Iliescu; Syed Wamique Yusuf; William Nassib William; Tarif H Khair; Juhee Song; Elie N Mouhayar
Journal:  J Am Coll Cardiol       Date:  2015-09-08       Impact factor: 24.094

6.  Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.

Authors:  Kan Yonemori; Hideo Kunitoh; Koji Tsuta; Tetsutaro Tamura; Yasuaki Arai; Yasuhiro Shimada; Yasuhiro Fujiwara; Yuko Sasajima; Hisao Asamura; Tomohide Tamura
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

7.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

8.  Mediastinoscope-controlled parasternal fenestration of the pericardium: definitive surgical palliation of malignant pericardial effusion.

Authors:  Imre Toth; Geza Szucs; Tamas F Molnar
Journal:  J Cardiothorac Surg       Date:  2012-06-19       Impact factor: 1.637

9.  Pericardial effusion and pericardiocentesis: role of echocardiography.

Authors:  Hae-Ok Jung
Journal:  Korean Circ J       Date:  2012-11-28       Impact factor: 3.243

10.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.